000134725 001__ 134725
000134725 005__ 20210129211722.0
000134725 0247_ $$2pmid$$apmid:23759368
000134725 0247_ $$2ISSN$$a1535-3508
000134725 0247_ $$2ISSN$$a1536-0121
000134725 0247_ $$2DOI$$a10.2310/7290.2013.00051
000134725 0247_ $$2wos$$aWOS:000336724400005
000134725 037__ $$aFZJ-2013-02822
000134725 041__ $$aeng
000134725 082__ $$a610
000134725 1001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b0$$eCorresponding author$$ufzj
000134725 245__ $$aEarlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-18F-Fluorethyl)-L-tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging.
000134725 260__ $$aHamilton, Ont.$$bDecker$$c2013
000134725 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1371797429_15725
000134725 3367_ $$2DataCite$$aOutput Types/Journal article
000134725 3367_ $$00$$2EndNote$$aJournal Article
000134725 3367_ $$2BibTeX$$aARTICLE
000134725 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000134725 3367_ $$2DRIVER$$aarticle
000134725 500__ $$3POF3_Assignment on 2016-02-29
000134725 520__ $$aAbstractAntiangiogenic treatment using bevacizumab in brain tumor patients may cause difficulties in the diagnosis of tumor progression (ie, nonenhancing tumor progression). Newly defined criteria for treatment assessment and diagnosis of tumor progression (ie, RANO [Response Assessment in Neuro-Oncology] criteria) have implemented signal alterations on T2/fluid-attenuated inversion recovery (FLAIR) sequences to changes in contrast enhancement. However, T2/FLAIR hyperintensity may be influenced by other causes (eg, radiation-induced leukoencephalopathy, peritumoral edema, gliosis). Positron emission tomography using the radiolabeled amino acid O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET-PET) may help detect the metabolically active tumor extent. We present 18F-FET-PET imaging findings in a glioblastoma patient during bevacizumab treatment suggesting an earlier diagnosis of tumor progression than magnetic resonance imaging changes, which are based on the RANO criteria.
000134725 536__ $$0G:(DE-HGF)POF2-332$$a332 - Imaging the Living Brain (POF2-332)$$cPOF2-332$$fPOF II$$x0
000134725 588__ $$aDataset connected to juser.fz-juelich.de, PubMed,
000134725 7001_ $$0P:(DE-HGF)0$$aRapp, Marion$$b1
000134725 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b2$$ufzj
000134725 7001_ $$0P:(DE-Juel1)156211$$aDunkl, Veronika$$b3$$ufzj
000134725 7001_ $$0P:(DE-HGF)0$$aSabel, Michael$$b4
000134725 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b5$$ufzj
000134725 773__ $$0PERI:(DE-600)2069848-3$$a10.2310/7290.2013.00051$$gVol. 12, no. 5$$n5$$p273-276$$tMolecular imaging$$v12$$x1535-3508$$y2013
000134725 8564_ $$uhttps://juser.fz-juelich.de/record/134725/files/FZJ-2013-02822_PV.pdf$$yRestricted$$zPublished final document.
000134725 909CO $$ooai:juser.fz-juelich.de:134725$$pVDB
000134725 9141_ $$y2013
000134725 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000134725 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000134725 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000134725 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000134725 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000134725 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000134725 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000134725 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000134725 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000134725 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich GmbH$$b0$$kFZJ
000134725 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000134725 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)156211$$aForschungszentrum Jülich GmbH$$b3$$kFZJ
000134725 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich GmbH$$b5$$kFZJ
000134725 9132_ $$0G:(DE-HGF)POF3-579H$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vAddenda$$x0
000134725 9131_ $$0G:(DE-HGF)POF2-332$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vImaging the Living Brain$$x0
000134725 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000134725 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000134725 980__ $$ajournal
000134725 980__ $$aVDB
000134725 980__ $$aUNRESTRICTED
000134725 980__ $$aI:(DE-Juel1)INM-3-20090406
000134725 980__ $$aI:(DE-Juel1)INM-4-20090406
000134725 981__ $$aI:(DE-Juel1)INM-4-20090406